Clinical trials: Anti-Retroviral Agents
Pregnancy Prevention
Continuous Use of COCs
The primary objective is to determine if continuous COC use leads to higher continuation rates over 12 months of follow up than use of the standard 28-day COC regimen.
- Trial name
- NCT00570440
- Testing
- Oral contraceptives--ethinyl estradiol, levonorgestrel
- Where
- 2 sites in Dominican Republic, Nicaragua
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- FHI 360
HIV Infections
Study to Evaluate Changes in CD4 on Replacing TDF With ABC or DDI+TDF With ABC+3TC
The study aims to ascertain whether the sole replacement of tenofovir with abacavir once a day improves the immunological response obtained with tenofovir + ddI or whether it is better to perform a double replacement of tenofovir…
- Trial name
- NCT00338390
- Testing
- Abacavir, Didanosine, Abacavir+Lamivudine
- Where
- 21 sites in Spain
- Volunteers
- 75 people
- Sponsor
- Hospital de Granollers
HIV-1 Infection, HIV Infections
Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.
Darunavir boosted with ritonavir (darunavir/r) is a powerful protease inhibitor, able to reduce the viral load in patients infected with multi-resistant HIV strains; In vitro and in vivo studies have shown that the induction of…
- Trial name
- RADAR (NCT00849160)
- Testing
- darunavir
- Where
- 5 sites in France
- Volunteers
- 100 people
- Sponsor
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
HIV Infection
TMC125-C211: Trial of TMC125 in HIV-1 Infected Subjects Who Were in a Sponsor Selected TMC125 Trial
This is a Phase II, open-label, roll-over trial to evaluate the long term safety and tolerability of TMC125, administered as part of an individually optimized antiretroviral therapy, in HIV 1 infected subjects.
- Trial name
- NCT00111280
- Testing
- TMC125
- Volunteers
- 48 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)
Demonstrate the safety and efficacy of Tipranavir/Ritonavir versus an active treatment regimen in highly treatment experienced Human Immunodeficiency virus 1(HIV-1) infected patients.
- Trial name
- NCT00054717
- Testing
- Tipranavir, Ritonavir(r), Comparator Protease Inhibitor (CPI)
- Where
- 117 sites in United States, Australia and 2 more
- Volunteers
- 630 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
A Study to Compare Two Different Anti-HIV Drug Regimens
This study compares 2 different anti-HIV drug regimens to determine which is the most effective in lowering the amount of HIV in the blood.
- Trial name
- NCT00000924
- Testing
- Ritonavir, Nelfinavir mesylate, Nevirapine
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection, Human Immunodeficiency Virus
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
Integrase is an enzyme produced by HIV so that the virus can multiply in the human body. GSK1349572 is a new drug in the integrase inhibitor class that prevents the enzyme from working properly and therefore prevents the virus…
- Trial name
- NCT00950859
- Testing
- GSK1349572 (Cohort I), GSK1349572 (Cohort II)
- Where
- 26 sites in United States, Canada and 3 more
- Volunteers
- 51 people
- Sponsor
- ViiV Healthcare
HIV-1 Infection
the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients
This study assess the safety, tolerability, and efficacy in reducing viral load and proviral DNA of UB-421 administered as an add-on to the ART in ART-experienced viremic HIV-1 subjects.
- Trial name
- NCT04041362
- Testing
- UB-421, Antiretroviral Therapy (ART)
- Sponsor
- United BioPharma
HIV Infections
Innovative Administration of Long-Acting Injectables for HIV Treatment Enhancement at Home
This study will support the expansion of long-acting injectable antiretroviral therapy (LAI-ART) in non-clinical settings by developing, implementing, and evaluating a comprehensive, theory-informed training intervention to…
- Trial name
- INVITE-Home (NCT06488846)
- Testing
- INVITE-Home, Clinic-Administered LAI-ART, Oral ART
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of California, San Francisco
HIV Care Loss to Followup, HIV Antiretroviral Therapy (ART) Adherence
Developing and Testing a Digital Health Tool for INterseCtional Stigma Assessment and Reduction at Multiple Levels and mUltiple DimEnsions (INCLUDE) to Improve HIV Care in ART Centers in Nepal
People living with HIV (PLWH) have poor clinical outcomes when they are excluded from care due to intersectional stigma related to HIV, mental health (MH), and other dimensions.
- Conditions
- HIV Care Loss to Followup, HIV Antiretroviral Therapy (ART) Adherence, HIV Stigma, Mental Health Conditions
- Trial name
- INCLUDE (NCT07370298)
- Testing
- INCLUDE
- Where
- Nepal
- Volunteers
- 88 people
- Sponsor
- Possible
HIV, Periodontal Diseases
The Impact of Oral Health in HIV Patients on Antiretroviral Therapy
This is a prospective cohort study designed to investigate the range of metabolic abnormalities observed in patients living with HIV on antiretroviral therapy.
- Conditions
- HIV, Periodontal Diseases, Caries, Non-communicable Disease
- Trial name
- OHART (NCT04645693)
- Where
- United States
- Volunteers
- 227 people
- Sponsor
- University of Pennsylvania
HIV Infections
Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir
The purpose of this study is to see if 3 anti-HIV drug combinations are safe and effective in patients who have failed previous anti-HIV treatments using nelfinavir (NFV).
- Trial name
- NCT00006326
- Testing
- Indinavir sulfate, Ritonavir, Delavirdine mesylate
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Agouron Pharmaceuticals
HIV Infections, Tuberculosis
Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis
The purpose of this study is to see if a type of anti-HIV therapy called HAART is effective in lowering levels of HIV and boosting the immune system in HIV-infected patients with tuberculosis (TB).
- Trial name
- NCT00004736
- Testing
- Nelfinavir mesylate, Ethambutol hydrochloride, Isoniazid
- Where
- 10 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years
This is a 48-week study to collect additional information on the safety, tolerability, pharmacokinetics, and antiviral activity of an investigational regimen (course of therapy) including FDA approved HIV drugs in HIV-infected…
- Trial name
- NCT00040664
- Testing
- ritonavir, fosamprenavir
- Where
- 42 sites in United States, Canada and 5 more
- Volunteers
- 69 people
- Sponsor
- ViiV Healthcare
HIV-1
Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine
Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes).
- Trial name
- MERIT (NCT00098293)
- Testing
- Maraviroc + Zidovudine/Lamivudine, Efavirenz + Zidovudine/Lamivudine, Maraviroc (UK-427,857) + Zidovudine/Lamivudine
- Where
- 144 sites in United States, Argentina and 12 more
- Volunteers
- 916 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients
The purpose of this study is to look at the effects of different anti-HIV drug combinations on body fat changes in HIV-positive patients who have never received anti-HIV therapy before.
- Trial name
- NCT00005106
- Testing
- Lamivudine/Zidovudine, Abacavir sulfate, Nelfinavir mesylate
- Where
- 39 sites in United States
- Volunteers
- 230 people
- Sponsor
- Glaxo Wellcome
HIV Infections, Dyslipidemias
Lipid Profile and Diabetes Mellitus in People With HIV
Traditional risk factors for cardiovascular diseases have been shown to have an even higher impact in the HIV infected population.
- Conditions
- HIV Infections, Dyslipidemias, Diabetes Mellitus, Cardiovascular Risk Factor
- Trial name
- NCT04125784
- Where
- Austria
- Volunteers
- 450 people
- Sponsor
- Moritz Oberndorfer
HIV/TB Co-infection
Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB
The purpose of the study is to evaluate the efficacy and safety of Nevarapine and Rifampicin vs Efavirenz and Rifampicin in antiretroviral naive patients co-infected with HIV and TB and to investigate whether Rifampicin…
- Trial name
- "NVP" (NCT01805258)
- Testing
- Nevirapine, Efavirenz
- Where
- India
- Volunteers
- 135 people
- Sponsor
- All India Institute of Medical Sciences
HIV-1 Infection
A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients
A double-blind, randomized, placebo-controlled, dose-escalating study to assess the antiviral activity, safety, tolerability, and pharmacokinetics (PK) of the CCR5 antagonist TBR 652 monotherapy dosed orally once daily (QD) for…
- Trial name
- NCT01092104
- Testing
- TBR-652, TBR-652 50 mg, TBR-652 75 mg
- Volunteers
- 52 people
- Sponsor
- Tobira Therapeutics, Inc.
HIV Infections
Phase 1 Pilot Study of an ART Bridging Regimen in Highly Experienced Patients Unable to Achieve Viral Suppression
We hypothesize that a simple bridging ARV regimen that tends to select for virus with a low replicative capacity may tend to stabilize CD4 cell counts and HIV viral load and might be an option to consider in patients with MDR…
- Trial name
- NCT00336778
- Testing
- 3TC, TDF, NLV
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Maryland, Baltimore
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.